share_log
Moomoo 24/7 ·  Apr 4 08:09
Achilles Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. The Company Announced Interim Phase I/IIa Data on the Use of Clonal Neoantigen Reactive T Cells From the CHIRON Study in Advanced Unresectable or Metastatic Non-small Cell Lung Cancer and the THETIS Study in Recurrent or Metastatic Malignant Melanoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment